David A. Reardon, MD

Given the current lack of positive phase 3 immunotherapy trials for glioblastoma, a misconception held by oncologists and neuro-oncologists is that immunotherapy has no place in this malignancy.

David A. Reardon, MD, discusses the design of a phase 1/2 trial with INO-5401 and INO-9012 in glioblastoma.

David A. Reardon, MD, discusses the role of INO-5401 and INO-9012 in glioblastoma.

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, institute physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses the immunogenicity of glioblastoma.

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the safety and efficacy data of an immunotherapy combination in glioblastoma.

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses a personalized neoantigen-targeting vaccine for patients with glioblastoma.

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses pembrolizumab (Keytruda) and bevacizumab (Avastin) for the treatment of patients with recurrent PD-L1–positive glioblastoma.

David A. Reardon, MD, clinical director at the Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the need for a new standard of care in the treatment landscape of glioblastoma multiforme.

David A. Reardon, MD, discusses results of a cohort from the open-label CheckMate-143 trial, which explored the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with recurrent glioblastoma multiforme (GBM).

Blockade of the PD-1/PD-L1 pathway is a novel and attractive treatment approach to many cancers, including malignant glioma, because of its potential to restore anti-tumor immunity.